In this video discussion with Pharmaceutical Executive, Michael J. Hennessy Jr., chairman and CEO of MJH Life Sciences, and Jason Brown, CEO of BPD Healthcare, discuss how the deal came together and what it means for healthcare executives navigating an increasingly complex marketplace.
Explore CEO insights on decision-making in manufacturing, focusing on risk management, packaging challenges, and strategies for product safety and quality.
Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.
Peptilogics Founder and CEO, Jonathan Steckbeck, explained that PLG0206’s membrane-active mechanism enables it to destroy both active and dormant biofilm bacteria overcoming a key limitation of traditional antibiotics.
Jesse Mendelsohn, executive vice president at Model N, explains the pros and cons of continuing to pursue DTC programs once the government-run program launches.
Peptilogics Founder and CEO, Jonathan Steckbeck noted that advances in peptide design and safety have positioned the field to address drug-resistant pathogens more effectively.
Peptilogics Founder, CEO, Jonathan Steckbeck, explained that PLG0206 stands apart from current treatments, while the company’s discovery platform transforms drug development from an iterative search process into a data-driven design model.
Jesse Mendelsohn, executive vice president at Model N, discusses how selling drugs directly to patients differs from traditional government programs.
BioLamina CEO Klaus Langhoff-Roos discusses the challenges of scaling stem cell production from lab plates to bioreactors, emphasizing the balance between cost, risk, and speed in advancing laminin-based technologies that could accelerate next-generation cell and gene therapies.
As timelines change, medical affairs teams must adjust their skillsets.
Hunter Smith,CFO of Rhythm Pharmaceuticals, noted that maintaining balance between investor expectations and long-term biotech priorities depends on partnering.
Efforts to regulate pharma prices will impact other sectors of healthcare, with PBMs likely to feel the impact.
Hunter Smith, CFO of Rhythm Pharmaceuticals, explains that in biotech, success often brings greater capital demands before profitability, requiring CFOs to balance continuous fundraising with careful management.
In discussing the evolving role of biotech CFOs, Hunter Smith,CFO of Rhythm Pharmaceuticals, emphasized that today’s finance leaders must act as the “voice of the investor,” ensuring disciplined capital allocation and long-term value creation.
The current administration’s efforts are just the latest attempt from the government to improve drug prices in the US.
Multiple pharma companies have already announced plans to invest in domestic projects.
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians.
Chris Spivey, Director of Industrial Relations and Strategic Partnerships for Industry Sciences One at MJH Life Sciences, and Raymond J. Deshaies, PhD, Executive Officer of Molecular Biology at the California Institute of Technology, discuss the development of MariTide, which is in development for obesity and type 2 diabetes.
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations.
As drug prices in the US fluctuate, pharma companies may look to other regions for opportunity.
Pharma companies have the choice of facing strict tariffs or negotiating with the current administration.
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection.
Gen Li, founder and president of Phesi, discusses how the industry is considering GLP-1s from a more holistic approach.
Gen Li, founder and president of Phesi, discusses how the rise of GLP-1 medications is impacting how various diseases are treated beyond the ones the medications are specifically designed to treat.
Craig Thompson, CEO of Cerevance touches on the NETSseq platform and how it shapes Cerevance's approach to the drug discovery strategy.
Craig Thompson, CEO of Cerevance discusses the key scientific and clinical insights that lead to Cerevance's pursuit of Solengepras.
The MFN executive order may result in the US losing its place as the friendliest market for innovation.
While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a large role in this area.
Ryan Quigley, CEO of Inizio, explains the impact of advancements and innovations and how they’re making pharma more personalized.
Peter Rubin discusses how effective President Trump’s executive order could actually be against the factors that dictate drug pricing.
